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To inform development of tuberculosis (TB) control 
strategies, we characterized a total of 2,261 Mycobacterium 
tuberculosis complex isolates by using multiple phenotypic 
and molecular markers, including polymorphisms in repeti-
tive sequences (spoligotyping and variable-number tandem 
repeats [VNTRs]) and large sequence and single-nucle-
otide polymorphisms. The Beijing family was strongly as-
sociated with multidrug resistance (p = 0.0001), and VNTR 
allelic variants showed strong associations with spoligotyp-
ing families: >5 copies at exact tandem repeat (ETR) A, >2 
at mycobacterial interspersed repetitive unit 24, and >3 at 
ETR-B associated with the East African–Indian and M. bo-
vis strains. All M. tuberculosis isolates were differentiated 
into 4 major lineages, and a maximum parsimony tree was 
constructed suggesting a more complex phylogeny for M. 
africanum. These ﬁ  ndings can be used as a model of patho-
gen global diversity. 
T
uberculosis (TB), caused by bacteria of the Mycobacte-
rium tuberculosis complex (MTBC), remains a global 
threat to human health, which causes an estimated 2 mil-
lion deaths annually (1). No horizontal gene transfer has 
been reported in MTBC, and the genome is more highly 
conserved than other pathogenic bacteria (2). Nevertheless, 
genotyping tools have recently identiﬁ  ed several polymor-
phisms in the MTBC genome that have provided insight 
into its evolution. Three major groups of MTBC genome 
alterations have been reported: single nucleotide polymor-
phisms (SNPs), large sequence polymorphisms (LSPs), and 
polymorphisms within repetitive sequences such as variable 
number tandem repeats (VNTRs). The ﬁ  rst 2 groups mark 
irreversible genetic events and can be used to construct phy-
logenies for M. tuberculosis (2–6). An association between 
geographic region and M. tuberculosis families, deﬁ  ned 
by speciﬁ  c polymorphisms, has been demonstrated. This 
geographic structuring producing genetically, and perhaps 
phenotypically, distinct MTBC populations may contribute 
to differences in clinical features such as severity of disease 
or prevalence of extrapulmonary disease (6–8) and should 
be considered during the development of new drugs and 
vaccines.
Sreevatsan et al. divided MTBC strains into 3 princi-
pal genetic groups (PGG1–PGG3) based on SNPs in codon 
463 of katG and codon 95 of gyrA (2). More recently, on 
the basis of polymorphisms in the oxyR, katG, and rpoB 
genes, strains have been divided into 5 lineages (I–IV and 
M. bovis); lineages I, III, and IV represent subgroups with-
in PGG1, and lineage II corresponds to PGG 2 and 3 (7). 
By combining these markers with LSPs RD239, RD105, 
RD750, RD711, and RD702, a small 7bp deletion in the 
pks15/1 gene and other SNPs, Gagneaux and Small were 
able to conﬁ  rm these M. tuberculosis lineages and 2 lineag-
es of M. africanum (6). The deletions RD9 and TbD1 are 
useful phylogenetic markers for other members of MTBC 
complex and ancestral M. tuberculosis strains (3). The loss 
and acquisition of repeats or spacers in the direct repeats 
region (9) does not appear to limit their value in biogeo-
graphic and phylogenetic studies (10,11).
Genotypic variation of MTBC strains at various geo-
graphic settings and signiﬁ  cant associations between certain 
allelic variants at VNTR loci, MTBC lineages, and spoli-
gotyping families have been reported (7,12–15). However, 
most studies used single genotyping methods on small pop-
ulations or convenience samples. Population-based studies 
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have focused primarily on areas of low- to middle-TB inci-
dence, and it is unclear whether the results are universally 
applicable (16–18). Larger population-based studies on 
geographically diverse populations are needed to establish 
the phylogenetic, epidemiologic, and clinical relevance of 
such associations.
London accounts for nearly half of all TB cases in 
the United Kingdom (≈3,300 cases in 2006; incidence rate 
44.8/100,000). Because 75% of these TB patients were 
born abroad (19), (Health Protection Agency update; www.
hpa.org.uk), and clinical signs of disease develop within 2 
to 3 years of arrival, we believe that the multicultural and 
diverse community in London provides a unique setting for 
studying the global biodiversity of MTBC. We aimed to 
establish whether MTBC isolates circulating in the Lon-
don population are a useful model of global diversity, to 
determine the phylogenetic relevance of polymorphisms in 
repetitive regions of the MTBC genome, especially for M. 
africanum and its position in TB evolution, and to investi-
gate associations between lineage and phenotype.
Materials and Methods
Study Design and Bacterial Isolates
One isolate from each of the 2,261 MTBC culture-pos-
itive patients was included in this prospectively designed 
population study. These isolates were collected from pa-
tients in all 30 London National Health Service hospitals 
between April 1, 2005, and March 31, 2006. Demographic 
data, including gender, date of birth, and country of birth 
were assigned to world regions according to an existing 
United Nations classiﬁ  cation (20). 
Identiﬁ  cation
Cultures were identiﬁ  ed by using standard phenotypic 
identiﬁ  cation tests (21) and molecular methods (Genotype 
Mycobacterium CM, AS, and MTBC kits; Hain Lifescience 
GmbH, Nehren, Germany) and the INNO LiPA Rif TB as-
say (Innogenetics, Ghent, Belgium) performed as recom-
mended by the manufacturer. DNA was extracted from 
cultures using chloroform extraction as described (22). Iso-
niazid, rifampin, ethambutol, streptomycin, pyrazinamide, 
and ciproﬂ  oxacin susceptibilities were determined by using 
the resistance ratio method (21). 
Genotyping
All extracts were typed by using automated 15 my-
cobacterial interspersed repetitive unit–VNTR (MIRU-
VNTR) fragment analysis (23–26). Clustered isolates were 
further genotyped by using an extended panel of 7 hyper-
variable VNTR loci (27). Data were exported to BioNu-
merics (Applied Maths, Sint-Martens-Latem, Belgium) for 
cluster analysis.
Spoligotyping was performed according to the manu-
facturer’s instructions (Isogen Lifescience, IJsselstein, the 
Netherlands) (9). Images were digitized and entered into 
BioNumerics software by using the BNIMA module (Ap-
plied Maths). Spoligotypes were assigned to families and 
subfamilies by using the online tools at http://cgi2.cs.rpi.
edu/~bennek/SPOTCLUST.html (10). We have used the 
established spoligotyping families Beijing, Central Asian 
(CAS), East African–Indian (EAI), and M. bovis as lineage 
designations, as well as European American (EuroAm) 
(13,28) for the M. tuberculosis lineage, which includes the 
X, T, LAM, S, and Haarlem families.
Other Methods
Detection of TbD1 and RD9 (3,13) was conducted by 
PCR fragment analysis (3). Reverse hybridization methods 
were used to analyze the 4 lineage-deﬁ  ning SNPs in 3 genes 
(oxyRC37T, katGC87A, rpoBT2646G, and rpoBC3243T) reported by 
Baker et al. (7) for selected isolates (n = 259) (12) and mu-
tations in katG, inhA, and rpoB genes associated with drug 
resistance (22).
Data were analyzed by using Excel, BioNumerics (Ap-
plied Maths), SPSS 12.0 (SPSS Inc, Chicago, IL, USA) 
software and online interactive statistical tools (www.
quantitativeskills.com/sisa/). Categorical variables were 
analyzed by using relative risks (RRs), odds ratios (ORs), 
and the χ2 test. Discrimination power of genotyping meth-
ods was assessed using the Hunter-Gaston index (29).
Results
Diversity within the Study Population
We studied 2,261 isolates, representing 95.7% of all 
the bacteriologically conﬁ  rmed TB cases reported in Lon-
don from April 1, 2005, through March 31, 2006. Using 
routine phenotypic and genotypic methods, we identiﬁ  ed 
99.1% (2,241) as MTBC; the remaining 20 were too heav-
ily contaminated for analysis.
Spoligotypes were generated for 98.8% (2,233) of 
the isolates; 656 types were identiﬁ  ed, of which 458 were 
unique and 198 were shared by groups of 2–221 isolates. 
Isolates were assigned to families and subfamilies on the 
basis of their spoligotype by using the online tools at http://
cgi2.cs.rpi.edu/~bennek/SPOTCLUST.html. All but 4 
spoligotypes were assigned to >1 of 36 groups; 88.4% of 
isolates were assigned to a single spoligotyping family or 
subfamily. The remaining 11.6% were assigned to 2 fami-
lies, albeit with given probabilities of <0.9. All the main 
spoligofamilies seen globally were represented within this 
population (Table 1).
Isolates were cultured from a variety of body sites; 57% 
were of pulmonary origin. Where known, 60% of isolates 
were cultured from male patients and 40% from female 
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patients; median age was 33 years. The COB was available 
for 1,381 (61.0%) patients; 1,157 (83.8%) were born in 89 
countries outside the United Kingdom (online Appendix Ta-
ble, www.cdc.gov/EID/content/16/2/272-app-T.htm). The 
population included representatives from all regions of the 
world (20).
VNTR Data as Phylogenic Markers
The 22 MIRU-VNTR genotypes, generated for 2,261 
isolates, resulted in 1,434 VNTR types representing the 
minimum number of independent strains within this pop-
ulation. Each type was designated an MTBC lineage on 
the basis of the VNTR types (12) (Figure 1). Where these 
lineages were ambiguous (n = 49), discordant to those 
suggested by spoligotype (n = 58), or not deﬁ  ned (n = 
210), SNP analysis was performed to resolve these dif-
ferences (n = 317). In all cases, the SNP analysis resolved 
the ambiguous VNTR lineage calling as 1 of the alterna-
tives producing the ambiguity. The SNP-deﬁ  ned lineage 
of strains discordant between the spoligotype and VNTR 
agreed with the VNTR call in 74.0% of cases. Finally, 
among the strains for which the VNTR was unable to 
deﬁ  ne any lineage, there was 94.0% agreement between 
the SNP and spoligotype-deﬁ  ned lineage (Table 1). All 
strains identiﬁ  ed as M. africanum were placed in the non-
deﬁ  ned group and had the SNP-1 genotype.
Spoligotyping gave a lineage that was conﬁ  rmed by an 
independent marker (VNTR or SNP) in 96.3% of isolates. 
VNTR gave an unambiguous lineage in 77.9% of strains; of 
these, 99% were conﬁ  rmed by an independent marker (spo-
ligo or SNP). Allelic variants were sought at each VNTR 
locus that best described each spoligofamily; those giving 
the highest sensitivities and speciﬁ  cities are shown in Table 
2. The highest sensitivities were seen in the LAM 1, LAM 
10, and Beijing families, which suggests their highly clonal 
and homogeneous nature. Several allelic variants showed 
strong associations with spoligo families, with >5 copies 
at ETR-A, >2 copies at MIRU24, and >3 copies at ETR-B 
associated with EAI and M. bovis (RR 2.99, 95% conﬁ  -
dence interval [CI] 2.51–3.56; RR 6.29, 95% CI 4.87–8.12; 
and RR 3.21, 95% CI 2.63–3.93, respectively), >3 copies at 
MIRU4 and 2 copies at MIRU26 with EAI (RR 2.31, 95% 
CI 1.98–2.70; and RR 12.8, 95% CI 8.41–17.90, respec-
tively), and 4 copies at MIRU23 with M. africanum and M. 
bovis (RR 220.3, 95% CI 82.07–591.50).
The presence of 2 copies at MIRU24 appears to be a 
good marker for EAI M. tuberculosis and non–M. tuber-
culosis members of the MTBC. This marker (number of 
copies in the locus MIRU24) was investigated in this popu-
lation by using the occurrence of the deletions RD9 and 
TbD1, which have previously been used as markers to dis-
tinguish these groups (Table 3). All 41 isolates identiﬁ  ed 
as M. africanum by spoligotype were also analyzed in this 
manner, 11 of which contained a single copy of MIRU24; 
296 M. tuberculosis isolates containing single and double 
copies of MIRU24 were analyzed as controls.
The deletion TbD1 was present in all EuroAm, CAS, 
and Beijing strains examined as well as some other M. tu-
berculosis isolates and absent from all M. africanum iso-
lates. The deletion RD9 was present in all M. bovis strains 
as well as some EAI and most M. africanum strains but 
absent from all other strains. Both deletions were absent 
from most EAI and some M. africanum strains (Table 3). 
Absence of RD9 deletion and 2 copies in MIRU24 was 
strongly associated with EAI spoligotype (RR 15.1, 95% 
CI 9.49–23.89). MTBC strains with the RD9 intact and 2 
copies in MIRU24 included both M. bovis and M. africa-
num spoligotypes, whereas strains with the RD9 intact and 
1 copy in MIRU24 formed a speciﬁ  c group of M. africa-
num originating presumably from the Indian subcontinent.
Using this data, and the SNP 1-MB and the MIRU24 enu-
meration data, we constructed a maximum-parsimony tree 
as shown in Figure 2.
Associations between Phylogenic 
Groups and Phenotype
Strong associations were seen between patient’s coun-
try of origin and the spoligo family of the isolate (online 
Appendix Table): CAS and EAI families dominated in 
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Figure 1. Mycobacterium tuberculosis complex lineages as 
determined by Gagneux et al. (6) and Baker et al. (7) deﬁ  ned by 
mycobacterial interspersed repetitive unit codes. MBOV, M. bovis; 
LAM, Latin American; CAS, Central Asian; EAI, East African–Indian; 
BCG, bacillus Calmette-Guérin; MAFR, M. africanum. The X, T, 
LAM, S, and Haarlem families are European American types.M. tuberculosis Strains and Phenotypes 
patients born on ISC (RR 2.4, 95% CI 2.02–2.74) as did 
Beijing and EAI families in patients born in Southeast Asia 
(RR 4.8, 95% CI 2.70–8.54). EAI families were seen in 
80.4% of isolates from patients born in East Africa and 
the ISC. The M. africanum family dominated in patients 
born in West Africa (RR 3.67, 95% CI 1.52–6.50). In con-
trast, LAM and Haarlem isolates were infrequently seen in 
patients born on the ISC (4.5% and 5.4%) and Southeast 
Asia (3.4% and 6.9%). T family isolates, one of the ge-
netic groups determined by spoligotyping, were distributed 
evenly across all regions except Southeast Asia, where they 
were infrequently seen. No association between lineage or 
spoligo family and pulmonary versus extrapulmonary site 
was seen in the present study.
Susceptibility to rifampin, isoniazid, ethambutol, strep-
tomycin, and pyrazinamide was evident for 98.9% (2,236) 
of the isolates. Of these isolates, 84.3% were sensitive to all, 
8.2% were isoniazid resistant, 5.4% streptomycin resistant, 
1.5% rifampin resistant, 0.7% ethambutol resistant, 0.5% 
pyrazinamide resistant, and 1.2% multidrug resistant.
Associations between spoligotype families and drug 
resistance of MTBC strains were analyzed by determin-
ing the minimum number of independent clones and the 
minimum number of resistance acquisition events within 
this population. VNTR15 cluster analysis was performed 
on all isolates (n = 2,261) to identify a single representative 
of each unique genotype. This analysis resulted in 1,166 
unique types.
When isolates shared a genotype but differed in sus-
ceptibility to a given drug, resistant and sensitive isolates 
were analyzed because the resistant isolate must have un-
dergone a genetic event and acquired a unique genotype. 
When genotypes for loci associated with isoniazid and ri-
fampin resistance had been determined and >1 type was 
present in a cluster, 1 of each type was included. Where 
members of a cluster and its nearest neighbor were resis-
tant, this was considered as a single acquisition event and 
only a single member was included. The resulting num-
bers divided between spoligotype families are shown in 
Table 4.
The M. bovis BCG family was associated with pyrazi-
namide (p<0.0001) and ethambutol resistance (p = 0.0009). 
Beijing family strains were associated with multidrug re-
sistance (p = 0.0001), isoniazid (p = 0.0019), and rifampin 
(p = 0.0027) resistance. Associations were seen between 
streptomycin resistance and the Beijing family (p = 0.0008) 
and between pyrazinamide (p = 0.0079) and streptomycin 
(p = 0.008) resistance and the LAM1 family.
Discussion
Several approaches have been used to study the global 
diversity of MTBC. One approach is to construct a global 
sample of isolates from reference collections around the 
world (19,30,31). In this instance, the degree of conﬁ  dence 
as to geographic origin of an isolate is high, but bias occurs 
1) where variety is limited to sites with which investigators 
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Table 1. Analysis of associations between Mycobacterium tuberculosis phylogenetic lineages defined by SNP analysis and 
spoligotyping families in the group of isolates not classified using VNTR codes, UK* 
Lineages (6,7) and relevant MIRU codes (12)
M. tuberculosis 
Spoligotypes
I/East Asian;
39–3, A–4, C–4 
II/European American; 
16–1,2,3, 39–2, B–1,2 
III/EAI;
23–5, C–2 
IV/Indo-Oceanic;  
24–2, 26–2 
M. bovis;
10–2, 40–2, 
C–5
H37Rv, n = 2  0 2 0 0 0
Beijing, n = 13  13 00 0 0
LAM, n = 17  0 17 00 0
T, n = 53  1
600740007764671† 
51 01
777200007403371† 
0
Haarlem, n = 21  0 20 01
777777774000731† 
0
EAI, n = 61  2
777777770003331† 
477777377413771† 
1
777734000000031† 
0 58 0
CAS, n = 18  0 0 18 00
X, n = 9  0 9 00 0
S, n = 2  0 2 00 0
Family 33, n = 4  1 1 0 2 0
Family 35, n = 7  7 00 0 0
Family 36, n = 5  0 5 00 0
M. bovis BCG, n = 4  0 0 0 0 4
M. africanum, n = 35  34 1
710044706302261* 
00 0
*SNP, single nucleotide polymorphism; VNTR, variable number tandem repeat; MIRU, mycobacterial interspersed repetitive unit; EAI, East African–
Indian; LAM Latin American; CAS, Central Asian. European American includes the X, T, LAM, S, and Haarlem families. 
†Octal codes indicate spoligotyping patterns for isolates with disagreements between SNP- and spoligotype-defined lineages. Dominant families within 
each lineage are in boldface.RESEARCH
have contact and 2) sites with high TB transmission, which 
often lack adequate facilities for bacteriologic culture. A 
second approach is to study isolates derived from a popula-
tion at a single geographic location whose members have 
diverse geographic origins throughout the world (19,30,31). 
In this instance, where country of birth data are used to 
indicate the geographic origin of an isolate, the degree of 
conﬁ  dence in this data may be lower, but MTBC isolates 
can be sampled at a wider range of geographic locations 
particularly from high TB incidence areas that have poor 
bacteriologic isolation facilities. Furthermore, additional 
data such as antimicrobial drug susceptibility and site of 
infection, useful for association studies, are retained and 
the quality of the data is ensured.
London is a cosmopolitan city where up to 30% of the 
population is foreign born (www.neighbourhood.statistics.
gov.uk), among whom 75% of TB cases are seen (19; HPA 
update, www.hpa.org.uk); a similar situation has been re-
ported in New York and Paris (19,30,31), although Lon-
don TB notiﬁ  cation rates (44.8 cases/100,000 population in 
2006) are generally higher than those for other high-income 
cities. We believe that London provides a suitable setting 
for studying global MTBC diversity because our study 
shows that TB patients came from 89 different countries 
276  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 2, February 2010
Table 2. Associations between Mycobacterium tuberculosis MIRU15 profiles and spoligotyping families and subfamilies, UK* 
MIRU15 allelic variants  Spoligotype
families 2 4 1 01 62 02 32 42 62 73 13 94 0 A B C
Se,
%
Sp,
%
Beijing 2 2 2; 3 2–4 2 5; 6 1 5–8 1–3 5 2–4 1–4 3; 4 2 4 80.0 99.9
CAS 2 2 Any 3-5 2 5 1 Any 3 4; 5 2; 3 1–4 3; 4 2 2 72.6 98.3
EAI1 2 Any 2-6 1–4 2 5 1 4–6 3 3; 5 2; 3 <5 2–4 2 2–4 77.0 85.4
EAI2 2 >3 4; 5 2; 3 2 6 2 2–4 3; 4 3–5 3; 4 2; 3 4; 6 >2 4 73.3 99.9
EAI3 2 >2 3; 4 1–5 2 6–8 2 2 3 4–6 2; 3 Any >4 1 3; 4 77.8 99.9
EAI4 2 2–6 4 2; 3 2 5; 6 2 2 1; 3 Any 1; 3 2; 3 >6 2–4 4 58.8 98.8
EAI5 2 1–9 3–6 2–4 2 >3 1–3 2 1–3 2–7 1–3 1–4 >4 2–7 2–4 75.0 98.3
MAF 2 2; 3 4–7 Any 2 4 1; 2 3–5 2–4 Any 2 1; 2 >3 2–4 4; 5 63.4 99.9
MBOV 2 1–3 2 3 2 4 2 5 2; 3 3 2 2 5 5–7 5 72.1 99.9
Haarlem1 2 2 2–6 2–4 1; 2 3; 5 1 4–7 3 3 2 2–5 2; 3 1; 2 3–5 66.7 89.2
Haarlem2 2 2 4; 5 1–3 1; 2 3–6 1 4; 5 1–3 3 2 1–4 2; 3 1; 2 3; 4 71.0 91.5
Haarlem3 2 2 2–6 1–4 1; 2 3; 5 1 4–6 3 2; 3 2 1–4 2–4 1; 2 2; 3 52.9 94.6
LAM1 2 2 3; 4 2 2 6 1 5; 6 2; 3 3 2 1 2 2 4 80.6 99.9
LAM10 2 2 2–4 2–4 1; 2 5 1 3–5 3 3 2 1–4 2–4 2 4 87.4 92.4
LAM3 2 2 4 2; 3 2 5; 6 1 4; 5 3 3 2 3 1; 2 2 2; 4 78.4 99.9
LAM5† 2 2 4 3 2 5 1 9 2 4 2 4 2 2 4 100.0 100.0
LAM7† 224326133323224 5 0 . 0 1 0 0 . 0
LAM8 2 2 2–5 1; 3 2 5 6 1 4; 5 1–3 3 2 1 2 1 4 66.2 99.4
LAM9 1; 2 2 2–4 1–3 1; 2 5–8 1 4–6 2; 3 2–4 2 Any 1–4 1; 2 2–6 72.7 77.1
S 2; 3 2; 3 3 2; 3 1–3 5; 6 1 4–6 3 2; 3 2 2; 4 4 2 4 44.4 99.8
T1 2 2; 3 Any Any 2 5; 6 1 <7 2; 3 2–4 2 Any 2–4 2 2–5 54.5 85.8
T2† 2 2 3; 5 3 2 5; 6 1 5 3 2; 3 2 1; 3 2; 3 2 3–5 100.0 98.3
T3 2 2 3–5 1–3 1; 2 5; 6 1 1; 5 3 3 2 2–5 3 2 4 60.5 95.7
T4 1; 2 2–4 2–4 3 1; 2 5; 6 0–2 4–5 2; 3 2–4 2 2–4 2; 4 1; 2 2–5 46.2 88.3
X1 2 2 3–6 3 1; 2 5; 6 1 1–7 3 2–4 2 2–7 3; 4 1; 2 2–5 61.4 92.3
X2 1; 2 1; 2 4 3 2 5 1 4–8 3; 4 2; 3 2 1–4 2; 3 2 2; 4 79.5 99.3
X3 2 2 3; 4 2; 3 2 5 1 4; 5 3 2; 3 2 2–5 3 2 3 66.7 99.0
*MIRU, mycobacterial interspersed repetitive unit; Se, sensitivity; Sp, specificity; CAS, Central Asian; EAI, East African–Indian; MAF, M. africanum;
MBOV, M. bovis; LAM, Latin American. The X, T, LAM, S, and Haarlem families are European American types. Any means any family or subfamily. Only 
strains with no secondary assignations to spoligotype groups were used for calculating associations. 
†Due to a small number of isolates in these families, Se and Sp values are calculated for illustrative purposes only. 
Table 3. Association between Mycobacterium tuberculosis spoligotypes, deletions, and allelic variants in the locus MIRU24, UK* 
Spoligotype families 
M. tuberculosis Deletion mapping and VNTR 
typing results  Mycobacterium bovis, n = 14  M. africanum, n = 41   EAI, n = 241  Other, n = 55 
TbD1+ 14 41 239 19
TbD1– 0 0 2 36
RD9+ 0 1 235 46
RD9– 14 40 6 9
MIRU24>2 14 30 240 24
MIRU24<1 0 11 1 31
*MIRU, mycobacterial interspersed repetitive unit; EAI, East African–Indian; VNTR, variable number tandem repeat. M. tuberculosis Strains and Phenotypes 
of origin, representing all regions of the world (20), includ-
ing areas that the World Health Organization has deﬁ  ned 
as having a high incidence of TB. The bacterial diversity 
within this population is shown by the presence of all the 
main spoligofamilies, although not all lineages are equally 
represented. Our study shows a disproportionate represen-
tation of patients from different regions; relatively small 
numbers were from the Americas.
Recent advances in molecular genotyping and com-
parative genomics have demonstrated that the level of ge-
netic variation in the MTBC may have been substantially 
underestimated. Rapidly evolving genomic regions such as 
VNTR and the direct repeat  region have been exploited for 
epidemiologic studies, whereas irreversible events recorded 
by SNPs and LSPs are of phylogenetic value (3,5–7). As-
sociations between polymorphisms in rapidly evolving ge-
nomic regions (VNTR or direct repeat region) and the SNP 
and LSP markers have been described (6,12,13,28,32–34). 
If the nature of these relationships could be clearly deﬁ  ned, 
large studies could be performed by investigating databases 
containing routine VNTR data.
Where lineages indicated by SNP and LSP analysis are 
congruent with spoligotype family names, we have retained 
these (as for CAS, EAI, Beijing, M. africanum and M. bo-
vis); for the lineages containing LAM, Haarlem, X,T, and 
S spoligo families, we have used the lineage designation 
EuroAm as suggested elsewhere (6). We have previously 
reported 10 VNTR loci (ETR A,B,C; MIRU10,16,23, 24, 
26,39,40) (12) capable of differentiating the MTBC into 4 
lineages (I–IV) and M. bovis (7).
VNTR analysis showed that 1,174 (81.9%) of 1,434 
independent strains could be grouped unambiguously into 
5 lineages. When the remainder were grouped by using the 
SNP analysis, a good correlation was seen between lineage 
and spoligotype family or group of families (Figures 1, 2).
Discrepancies between lineage and spoligo family 
mainly resulted from limitations imposed by the family 
designation software, choice of genetic targets analyzed, or 
overlapping rules deﬁ  ning some spoligo families. Strains 
belonging to families 33–36 and EAI 1 appeared in mul-
tiple lineages. These spoligotype families were designated 
as low probability, which suggests that the model spoligo-
type was detecting unrelated events in different families. In 
rare cases, discrepancies will be seen where genetic events 
converge to give identical types in unrelated strains. In the 
present study this can be seen when multiple lineages are 
indicated by VNTR or spoligotypes.
Discrepancies will also occur where the VNTR/SNP 
system fails to distinguish between spoligotype families. 
The most striking of these are the strains identiﬁ  ed as M. 
africanum by spoligotype but as the Beijing lineage be-
cause of the presence of SNP1. We resolved this problem 
by constructing a maximum-parsimony tree (Figure 2) us-
ing the 5 SNP, LSP, and MIRU24 repeat numbers. The 
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Table 4. Minimum number of unique types seen within each Mycobacterium tuberculosis spoligotype family, by resistance or 
susceptibility to 5 antimicrobial drugs, United Kingdom* 
No. types, by drug resistance or drug susceptibility 
Spoligotype family  STR-R STR-S INH-R INH-S ETH-R ETH-S RIF-R RIF-S PZA-R PZA-S MDR+ MDR–
Beijing 10 40 13 38 3 43 5 43 1 45 5 45
CAS 14 202 30 198 1 206 3 206 2 206 3 206
EAI 8 244 23 234 3 247 4 247 1 248 4 247
European American 45 451 59 441 5 475 19 467 6 474 10 470
M. bovis B C G 062415152315
Family 33–36 5 39 4 41 1 43 1 43 0 44 1 44
M. africanum 2 22 0 22 0 22 0 22 0 22 0 22
*STR, streptomycin; R, resistant; S, susceptible; INH, isoniazid; ETH, erythromycin; RIF, rifampin; PZA, pyrazinamide; MDR, multidrug-resistant; CAS, 
Central Asian; EAI, East African–Indian; BCG, bacillus Calmette-Guérin.  
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Figure 2. Maximum-parsimony tree constructed based on 3 
independent sets of markers: large sequence polymorphisms 
(LSPs), single nucleotide polymorphisms (SNPs), and number of 
repeats in the locus 24 using the following assumptions: 1) SNPs 
are irreversible unique events; 2) LSPs are irreversible rare events; 
3) spoligotypes are not produced by convergent events; and 4) 
variable number tandem repeat (VNTR) loci can both acquire 
and lose repeats. EAI, East African–Indian; MIRU, mycobacterial 
interspersed repetitive unit code; EuroAm, European American; 
CAS, Central Asian; MBOV, M. bovis; MAFR, M. africanum; BCG, 
bacillus Calmette-Guérin. The X, T, LAM, S, and Haarlem families 
are European American types.RESEARCH
MIRU24 repeat numbers appear to play a phylogenetic 
role, as shown in this study (Table 3) and previous studies 
(13,15) in which >2 repeats are markers for EAI2–EAI5 
(but not EAI1), M. tuberculosis, and M. bovis strains. 
In its construction, we made the assumptions that SNPs 
mark irreversible unique events and that VNTR loci can 
acquire and lose repeats. A BCG strain isolated from a pa-
tient from London (not included in this study) contained 
the TbD1 deletion, demonstrating clearly that these de-
letion events are not unique. Therefore, the assumption 
that LSPs are infrequent irreversible events was made. 
The strains in this study are of human origin and therefore 
are mainly M. tuberculosis and M. africanum, hence the 
focus of the phylogenetic scenario. The tree shown here 
is concordant with previous scenarios (3,6) differing only 
in the diversity seen in strains identiﬁ  ed as M. africanum. 
All these strains contained SNP1 and were identiﬁ  ed on 
the basis of the loss of spoliogotype spacers 8, 9, and 39 
but contained either 1 or 2 copies of MIRU24 and the 
presence and absence of RD9, resulting in 3 types. The 
absence of the TBD1 deletion distinguishes M. africanum 
strains from Beijing strains.
EAI strains may represent the ancestral MTBC type 
(6,15). The data presented here suggest that M. africanum 
competes for this distinction. The types containing 2 copies 
of MIRU24, with and without RD9 originate exclusively 
from West Africa, suggest that these may be indigenous to 
this region. M. africanum species have traditionally been 
phenotypically subdivided into 2 subgroups, Type 1 (West 
African) and Type 2 (East African) (34). Recent genetic 
analysis suggests that M. africanum Type 2 (East African) 
is a phenotypic variant of M. tuberculosis and relatively 
distant from M. africanum Type 1 (West African), which 
is characterized by a deleted RD9, an intact TbD1 region, 
and speciﬁ  c SNPs in katG and gyrA genes (35,36). Our data 
suggest a more complex phylogeny of M. africanum Type 
1 (West African). This phylogeny is complicated further by 
strains with a deleted RD9 and a single copy of MIRU24 
originating predominantly from the Indian subcontinent.
The VNTR numbers seen within each spoligo family 
are shown in Table 3. From these data, lineage-dependent 
VNTR locus plasticity can be seen. This plasticity ranges 
from 7/15 loci showing variation within the CAS to 14/15 
showing variation in the EuroAm lineage. VNTR loci 
such as MIRU10 and 16 show variation across all fami-
lies, whereas MIRU27 shows variation in CAS alone. The 
distribution of repeat numbers at each locus within each 
lineage suggests the variation seen has arisen by stepwise 
mutations of a lineage founder strain. It is likely that the 
VNTR proﬁ  les used to predict spoligotype family at the 
highest speciﬁ  city (Table 2) represent this type.
Using country of birth as a surrogate for geographic 
origin of an infecting strain, we saw strong associations 
with the lineage/spoligo family of isolates (online appen-
dix Table). The data here conﬁ  rm published data that Bei-
jing strains were associated with patients originating from 
Southeast Asia; EAI with patients from Southeast Asia, 
the Indian subcontinent, and East Africa; CAS with pa-
tients from the Indian subcontinent; and EuroAm with a 
global distribution of patients (7,32). This global geograph-
ic structuring may explain the apparent geographic varia-
tion in efﬁ  cacy of the M. bovis BCG vaccine.
It has been long questioned whether there is an asso-
ciation between site and progression of infection and bac-
terial genotype; some evidence supports this association 
(37,38). Our study showed no association between lineage 
or spoligo family and site of infection.
That the M. bovis family was associated with pyrazi-
namide resistance would be expected because resistance is 
a deﬁ  ning characteristic for most of the group (although 
not for M. bovis subsp. caprae). Beijing family isolates 
were associated with multidrug resistance and streptomy-
cin resistance. The association with multidrug resistance 
has been reported (8), but the evidence presented here is 
particularly compelling, given that all strains used in the 
analysis were individual types. The value of this approach 
was demonstrated by analyzing LAM10 isolates, a family 
to which a highly successful clone of isoniazid-resistant M. 
tuberculosis responsible for >250 cases in northern London 
(38) belongs. Eight isolates were identiﬁ  ed in this study. 
When all isolates belonging to this group were analyzed, 
LAM10 was strongly associated with isoniazid resistance 
(p<0.00001), but when a single representative of each 
cluster was used this association disappeared. The Beijing 
lineage would appear to have a predisposition toward the 
acquisition of drug resistance rather than the drug-resistant 
clones being transmitted more frequently. The extent of the 
geographic regions used in the association study make it 
unlikely that this predisposition is entirely due to local TB 
control and treatment practices. 
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